iZMYND8-34
Based on 1 Customer Validation
iZMYND8-34 is a ZMYND8 inhibitor with an IC50 of 0.66 μM. iZMYND8-34 inhibits the binding of H3K4me1–H3K14ac peptide to the ZMYND8 protein. iZMYND8-34 inhibits ZMYND8’s histone recognition. iZMYND8-34 blocks neuroendocrine prostate cancer development.
For research use only. We do not sell to patients.
- Purity: 98.81%
- CAS No.: 1358901-59-3
- Formula: C22H19N5O6
- Molecular Weight:449.42
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
iZMYND8-34 binds to recombinant ZMYND8-PBP with a dissociation constant (Kd) of 1.73 μM[1].
iZMYND8-34 exerts negligible effects on luminal C4-2 and 22Rv1 cells, but significantly inhibits the growth of NE1.3 cells, TKO and ST88 organoids[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
iZMYND8-34 (10 mg/kg; i.p.; every 2 days; 4 weeks; in combination with Enzalutamide (HY-70002)) potently inhibits ADT-induced NEPC transdifferentiation in mice, reduces tumor growth, and extends survival in the LTL-331 PDX model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male; 6-week-old; genetically engineered: ProbasinCre/+; Ptenflox/flox; Trp53flox/flox; Rb1flox/flox)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every 2 days; 6 weeks
-
Result:Significantly extended mouse survival (log-rank test, P < 0.0001).
Reduced end-stage tumor volume.
Shifted tumor histology from predominantly NEPC to adenocarcinoma or prostatic intraepithelial neoplasia.
Eliminated NEPC cell populations (CHGA+KRT8-AR- cells).
Reduced expression of NE markers (SYP, CHGA).
Restored AR expression.
Completely prevented metastatic spread to lymph nodes, lungs, and liver.
-
Animal Model:NSG (male; 6-week-old; castrated; subcutaneous implantation of LTL-331 PDX)[1]
-
Dosage:10 mg/kg (in combination with enzalutamide)
-
Administration:i.p.; every 2 days; 4 weeks
-
Result:Significantly inhibited LTL-331 PDX tumor growth.
Extended mouse survival.
Reduced the percentage of CHGA+ NEPC cells.
Decreased Ki67+ proliferating cells compared to vehicle control.
Chemical Information
-
CAS No. 1358901-59-3
-
Appearance Solid
-
Molecular Weight 449.42
-
Formula C22H19N5O6
-
Color White to off-white
-
SMILES
O=C(C1=C2N(C)C(N(C3=CC=C(OCO4)C4=C3)C2=NC(C5=CC=CC(OCC)=C5O)=N1)=O)N
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 10 mg/mL (22.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2251 mL | 11.1255 mL | 22.2509 mL | 55.6273 mL |
| 5 mM | 0.4450 mL | 2.2251 mL | 4.4502 mL | 11.1255 mL | |
| 10 mM | 0.2225 mL | 1.1125 mL | 2.2251 mL | 5.5627 mL | |
| 15 mM | 0.1483 mL | 0.7417 mL | 1.4834 mL | 3.7085 mL | |
| 20 mM | 0.1113 mL | 0.5563 mL | 1.1125 mL | 2.7814 mL |
iZMYND8-34 Related Classifications
HY-403538 Related Classifications
Powered by Bioz